Skip to main content
. 2022 Aug 11;316:245–253. doi: 10.1016/j.jad.2022.08.017

Table 2.

Clinically significant symptoms of depression, anxiety, and co-morbid symptoms in pregnant and postpartum women during the COVID-19 pandemic.

Pregnant women
Postpartum women
Depression
Anxiety
Co-morbid symptoms
Depression
Anxiety
Co-morbid symptoms
EPDS ≥13
n (%)
GAD-7 ≥10
n (%)
EPDS ≥13 & GAD-7 ≥10
n (%)
EPDS ≥13
n (%)
GAD-7 ≥10
n (%)
EPDS ≥13 & GAD-7 ≥10
n (%)
Overall 889 (26.7) 665 (20.0) 504 (15.2) 1288 (32.7) 1049 (26.6) 799 (20.3)
Brazil 101 (37.7) 92 (34.3) 72 (26.9) 282 (47.2) 250 (41.9) 197 (33.0)
Chile 60 (34.9) 62 (36.0) 47 (27.3) 92 (33.8) 113 (41.5) 76 (27.9)
Cyprus 40 (18.2) 30 (13.6) 19 (8.6) 56 (22.5) 40 (16.1) 28 (11.2)
Greece 64 (19.0) 51 (15.1) 30 (8.9) 90 (23.9) 96 (25.5) 66 (17.6)
Israel 60 (27.5) 33 (15.2) 27 (12.4) 69 (20.6) 41 (12.3) 31 (9.3)
Portugal 183 (24.3) 149 (19.8) 115 (15.3) 188 (28.1) 151 (22.6) 116 (17.3)
Spain 93 (26.3) 104 (29.5) 69 (19.5) 159 (33.5) 160 (33.7) 113 (23.8)
Turkey 225 (27.9) 102 (12.7) 86 (10.7) 216 (34.8) 101 (16.3) 91 (14.7)
UK 63 (31.7) 42 (21.1) 39 (19.6) 136 (39.3) 97 (28.0) 81 (23.4)

EPDS = Edinburgh Postnatal Depression Scale; GAD-7 = Generalized Anxiety Disorder Screener; UK = United Kingdom. Sample sizes in the pregnant women group: EPDS valid data: n = 3326; GAD-7 valid data: n = 3325; sample sizes in the postpartum women group: EPDS valid data: n = 3939; GAD-7 valid data: n = 3937.